When addressing Clay Siegall’s contribution to the field of medicine, it demonstrates how influential and important he is to his patients. As co-founder of Seattle Genetics in 1998, Siegall’s aim is to improvement medical treatment for cancer patients. By recognizing some of Siegall’s achievements as well as how he perceived by the media, it will prove that he is a renowned medical scientists, determined to improve the lives of cancer patients.
As President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Clay Siegall devotion is to drug developmental practices. Some of these practices include developing the antibody-drug conjugates (ADC’s), as well as securing FDA approval of the first ADC product, mentioned on Seattle Genetics website. This is part of his role in the cancer research community, which he has successfully done.
Clay Siegall has also been publicly recognized for continuing to expand Seattle Genetics drug cancer treatments, which has also led to influx of hiring more employees, according to Bizjournal.com. In other news, Siegall has also been mentioned in NBC News as well as Bloomberg.com. In blogs Siegall has been mentioned favorable for his fearless devotion to fighting cancer, according to Funkdafunk.com. He is also mentioned in another blog by Michael Haltman, who offers investment tips and tricks, explains the positive work Siegall went through to form Seattle Genetics.
While Clay Siegall no longer has a Facebook page, he is mentioned in an article on Facebook that is related to George Washington University School of Medicine and Health Sciences. This talks about when he started researching cancer therapies. The article does not mention any reviews about the article. But the article overall on Facebook highlights the influential work of Siegall and where his passion is derived from.
By addressing Clay Siegall’s work and accomplishments in cancer therapies, it ultimately demonstrates how influential he has become among the cancer research community. His involvement with Seattle Genetics, which now has successfully marketed ADCs globally. Seattle Genetics has also successfully secured 1.2 billion dollars for funding. It truly addresses Siegall’s powerful influence and what he has accomplished.